Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
IPO Year: 2018
Exchange: NASDAQ
Website: orchard-tx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/29/2021 | $12.00 → $9.00 | Overweight | Cantor Fitzgerald |
11/16/2021 | Neutral → Underweight | JP Morgan | |
11/5/2021 | $15.00 → $13.00 | Outperform | Oppenheimer |
8/18/2021 | Overweight → Neutral | JP Morgan |
TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 7-11, 2024, in Baltimore. Featured data include several accepted abstracts and an Oral Presidential Symposium supporting the safety and efficacy of atidarsagene autotemcel (formerly OTL-200 which was recently approved as Lenmeldy™ in the
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, has been named to the inaugural 2024 TIME100 Health, an annual list recognizing the impact, innovation, and achievement of the world's most influential individuals in health this year. The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/. "I am incredibly humbled, privileged, and immensely proud to b
Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout the treatment process Lenmeldy wholesale acquisition cost of $4.25 million for one-time treatment reflects its clinical, economic and societal value Innovative outcomes- and value-based agreements are being offered to both private and government insurers to ensure broad, expedient and sustainable reimbursed access TOKYO, LONDON and BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the de
TOKYO and LONDON and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the U.S. Food and Drug Administration (FDA) has approved Lenmeldy™ (atidarsagene autotemcel), formerly known as OTL-200, for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD). "The FDA approval of Lenmeldy opens up tremendous new possibilities for children in the U.S. with early-onset MLD w
- Fundraise closed above its original target, reflecting strong interest from institutional, strategic and high net worth investors globally ORI Capital today announced the final close of its second fund, ORI Fund II (the "Fund"), with total commitments of $260 million. This milestone meets the Fund's original target and underscores strong investor confidence in ORI Capital's investment strategy and track record. NATICK, Mass. Founded in 2015, and led by veteran investor, Simone Song, ORI Capital is well-positioned to identify and nurture the next generation of innovative companies. The Fund will invest in innovative early-stage biotech companies globally, across the areas of diagnostic
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient's own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S. and Europe TOKYO, LONDON and BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the first patient has been randomized at the M Health Fairview Masonic Children's Hospital in a registrational trial evaluating the efficacy and safety of OTL-203, an investigational hemat
BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced 10 presentations from across its neurometabolic portfolio will be featured at the 20th Annual WORLDSymposium™ taking place February 4-9, 2024, in San Diego, California. Featured presentations include updated neurocognitive and biochemical results from an ongoing proof-of-concept study of investigational OTL-201 in mucopolysaccharidosis type IIIA (MPS-IIIA), also known as Sanfilippo syndrome type A, with median follow-up now extending to 2.75 y
BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD). The agreement covers several member countries, including Belgium, The Netherlands, and Ireland. It follows similar arrangements made with reimbursement authorities in the United Kingdom (UK), Italy, Germany, Sweden, Iceland, Finland and Norway, and is a key component of the company's
TOKYO and LONDON and BOSTON, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) discovering and developing novel medicines utilizing the latest biotechnology, and Orchard Therapeutics plc ((Orchard Therapeutics, NASDAQ:ORTX), a global gene therapy leader, today announced Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics. The acquisition of all outstanding shares of Orchard Therapeutics by way of a Scheme of Arrangement procedure under the UK Companies Act 2006 was completed on January 24, 2024, and Orchard Therapeutics has become a wholly-owned subsidiary of Kyowa Kirin.
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public company and accelerate growth SARASOTA, Fla. and AVENTURA, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, a healthcare services company focused on expanding access to advanced fertility treatment worldwide, which has recently signed a definitive merger agreement with NAYA Biosciences ("NAYA") to establish an expanded, publicly traded life science company, today announced that it has filed S-4 registration and preliminary joint proxy statements in connection with the upcoming merger.
15-12G - Orchard Therapeutics plc (0001748907) (Filer)
EFFECT - Orchard Therapeutics plc (0001748907) (Filer)
EFFECT - Orchard Therapeutics plc (0001748907) (Filer)
S-8 POS - Orchard Therapeutics plc (0001748907) (Filer)
S-8 POS - Orchard Therapeutics plc (0001748907) (Filer)
S-8 POS - Orchard Therapeutics plc (0001748907) (Filer)
S-8 POS - Orchard Therapeutics plc (0001748907) (Filer)
S-8 POS - Orchard Therapeutics plc (0001748907) (Filer)
S-8 POS - Orchard Therapeutics plc (0001748907) (Filer)
POS AM - Orchard Therapeutics plc (0001748907) (Filer)
TOKYO and LONDON and BOSTON, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) discovering and developing novel medicines utilizing the latest biotechnology, and Orchard Therapeutics plc ((Orchard Therapeutics, NASDAQ:ORTX), a global gene therapy leader, today announced Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics. The acquisition of all outstanding shares of Orchard Therapeutics by way of a Scheme of Arrangement procedure under the UK Companies Act 2006 was completed on January 24, 2024, and Orchard Therapeutics has become a wholly-owned subsidiary of Kyowa Kirin.
-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin's portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)--Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a total maximum equity value of approximately $477.6 million--Kyowa Kirin to host investor conference call on Oct 5 at 18:30 p.m. JST- TOKYO and LONDON and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Ky
Reported $6.6M in Q2'23 Libmeldy net sales, representing the highest quarter to date $34.0M of additional capital from second closing of strategic financing extends runway to mid-2025 Four MLD patients identified from ~150,000 newborns screened in prospective studies suggests significantly higher incidence than previously estimated in the medical literature Six presentations at ASGCT demonstrate the ability of HSC gene therapy to address neurometabolic and CNS disorders, as well as larger indications Company to host conference call and live webcast today at 8:00 a.m. EDT BOSTON and LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene th
BOSTON and LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 3, 2023, at 8:00 a.m. EDT to review business updates and its second quarter 2023 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. Analysts wishing to participate in the question and answer session should use this link to register. A replay of the webcast will be archived on the Orchard website following the presentation. About Orchard TherapeuticsAt Orchard Therapeutics,
New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of motor skills Updated OTL-201 data from ongoing proof-of-concept study in MPS-IIIA patients show additional favorable neurocognitive outcomes compared to disease natural history with median follow-up of 2.5 years First preclinical data for OTL-204 highlight ability of HSC gene therapy to restore microglial function, modulate neuroinflammation, and normalize predictive biomarkers in the progranulin form of frontotemporal dementia (GRN-FTD) Company to host conference call and web
Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn's disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of CAR-Treg cells from genetically engineered HSCs as a potential one-time treatment for autoimmune disorders Company to host conference call and webcast Tuesday, May 23 at 8:00 a.m. EDT BOSTON and LONDON, May 18, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today presented new data from the company's hematopoietic stem cell (HSC) gene therapy research pipeline targeting larger indications at the ongoing 26th Annual Meeting of the American Society
OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) Strategic financing from leading healthcare investors provides up to $188 million of additional capital upon achievement of key milestones $18.8M of Libmeldy revenue in 2022 with growth expected in 2023 from ongoing commercial expansion activities in Europe Newborn screening studies have confirmed three cases of metachromatic leukodystrophy (MLD) with 96,000 babies screened globally to date Company to webcast conference call today at 8:00 a.m. ET BOSTON and LONDON, March 06, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX)
All patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up Four out of five patients demonstrated gain of cognitive skills in line with development in healthy children with one patient showing a marked improvement compared to disease natural history Treatment with OTL-201 was generally well-tolerated Company to host conference call and webcast at 5:00 p.m. EST BOSTON and LONDON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced early clinical findings, including the first neurocognitive results, from its ongoing proof-of-concept (PoC) study of OTL-201, an
BOSTON and LONDON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Monday, November 14, 2022, at 8:00 a.m. EST to review business updates and its third quarter 2022 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. The conference call can be accessed by dialing (800) 715-9871 (toll-free) or (646) 307-1963 (toll) and using the conference ID 8411062. A replay of the webcast will be archived on the Orchard website following the presentation. About Orchard T
Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven upcoming presentations at ASGCT highlight application of HSC approach including clinical and research programs Cash and investments of approximately $200M provide runway into 2024 BOSTON and LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced recent business highlights along with its financial results for the qua
Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first quarter of 2024 Biologics License Application for OTL-200 in MLD accepted by U.S. FDA under Priority Review; PDUFA date set for March 18, 2024 Ten prospective newborn screening studies are active globally with approximately 200,000 babies screened Eight presentations at ESGCT highlighted the differentiated profile and potential broad applicability of the company's HSC gene therapy platform BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene the
PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed biotechsBritish Patient Capital invests £10 million in a Series B extension bringing total raised in this round to £85.5 million Oxford, United Kingdom – 15 May 2023 – OMass Therapeutics (‘OMass', or ‘the Company'), a biotechnology company that identifies medicines against highly validated target ecosystems, today announces the appointment of Jim Geraghty as chairman of its board of directors and an additional investment of £10 million from new inve
Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce company's strategic focus on innovation in the areas of discovery, clinical development and manufacturing BOSTON and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the appointment of two gene therapy and industry experts, Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., to serve as chief scientific officer and chief technical officer, respectively
BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Parker will oversee all aspects of commercial strategy, planning and operations for the company. Mr. Parker is a seasoned commercial leader with more than 20 years of experience in the healthcare and biotech industry, including deep rare disease and gene therapy experience. Mr. Parker’s previous positions include commercial leadership roles at Celgene, NPS Pharma (Shire) and PTC Therapeutics, where he led the company’s first U.S. product launch in Duchenne
SC 13G - Orchard Therapeutics plc (0001748907) (Subject)
SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)
SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)
SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)
SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)
SC 13G - Orchard Therapeutics plc (0001748907) (Subject)
SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)
SC 13G - Orchard Therapeutics plc (0001748907) (Subject)
SC 13G - Orchard Therapeutics plc (0001748907) (Subject)
SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
4 - Orchard Therapeutics plc (0001748907) (Issuer)
Cantor Fitzgerald resumed coverage of Orchard Therapeutics with a rating of Overweight and set a new price target of $9.00 from $12.00 previously
JP Morgan downgraded Orchard Therapeutics from Neutral to Underweight
Oppenheimer reiterated coverage of Orchard Therapeutics with a rating of Outperform and set a new price target of $13.00 from $15.00 previously
JP Morgan downgraded Orchard Therapeutics from Overweight to Neutral
JPMorgan Chase & Co. resumed coverage of Orchard Therapeutics with a rating of Overweight and set a new price target of $15.00 from $14.00 previously
JP Morgan resumed coverage of Orchard Therapeutics with a rating of Overweight and set a new price target of $15.00 from $14.00 previously
JP Morgan resumed coverage of Orchard Therapeutics with a rating of Overweight
Stifel initiated coverage of Orchard Therapeutics with a rating of Buy and set a new price target of $12.00
Stifel Nicolaus initiated coverage of Orchard Therapeutics with a rating of Buy
The acquisition of all outstanding shares of Orchard Therapeutics by way of a Scheme of Arrangement procedure under the UK Companies Act 2006 was completed on January 24, 2024, and Orchard Therapeutics has become a wholly-owned subsidiary of Kyowa Kirin.
Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, for the treatment of early-onset metachromatic leukodystrophy (MLD).
- SEC Filing
Orchard Therapeutics (NASDAQ:ORTX) reported its Q3 earnings results on Monday, November 13, 2023 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Orchard Therapeutics beat estimated earnings by 80.0%, reporting an EPS of $-0.15 versus an estimate of $-0.75. Revenue was down $218 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $1.6 which was followed by a 1.72% increase in the share price the next day. To track all earnings releases for Orchard Therapeutics visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.
U.S. stocks traded slightly lower toward the end of trading, with the Dow Jones index falling around 40 points on Thursday. The Dow traded down 0.12% to 33,088.44 while the NASDAQ fell 0.23% to 13,206.10. The S&P 500 also fell, dropping, 0.23% to 4,253.86. Check This Out: Top 4 Financial Stocks You'll Regret Missing This Month Leading and Lagging Sectors Real estate shares rose by 0.5% on Thursday. In trading on Thursday, consumer staples shares dipped by around 1.8%. Top Headline ConAgra Brands Inc (NYSE:CAG) reported better-than-expected earnings for its first quarter on Thursday. The company posted quarterly sales of $2.90 billion, flat Y/Y, versus the consensus of $2
Gainers Orchard Therapeutics (NASDAQ:ORTX) shares increased by 96.5% to $15.99 during Thursday's regular session. As of 13:31 EST, Orchard Therapeutics's stock is trading at a volume of 7.9 million, which is 17105.9% of its average full-day volume over the last 100 days. The company's market cap stands at $363.4 million. Histogen (NASDAQ:HSTO) shares moved upwards by 47.17% to $0.75. Trading volume for Histogen's stock is 414.2K as of 13:31 EST. This is 163.7% of its average full-day volume over the last 100 days. The company's market cap stands at $3.1 million. Clene (NASDAQ:CLNN) stock moved upwards by 21.0% to $0.6. Trading volume for this security as of 13:31 EST is 2.1 million, which
Gainers Orchard Therapeutics plc (NASDAQ:ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS. Meiwu Technology Company Limited (NASDAQ:WNW) gained 69.4% to $0.1641. VS MEDIA Holdings Limited (NASDAQ:VSME) climbed 66% to $7.74. VS Media announced its expansion into Macau. SP Plus Corporation (NASDAQ:SP) shares gained 47.5% to $52.24 after Metropolis Technologies announced it will acquire the company for $1.5 billion. Camber Energy, Inc. (NYSE:CEI) jumped 40% to $0.3470. Better Choice Company Inc. (NYSE:BTTR) shares climbed 37.5% to $0.2198 after gaini
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.45% to 32,980.31 while the NASDAQ fell 0.62% to 13,154.24. The S&P 500 also fell, dropping, 0.57% to 4,239.60. Check This Out: Top 4 Financial Stocks You'll Regret Missing This Month Leading and Lagging Sectors Energy shares fell by just 0.2% on Thursday. In trading on Thursday, consumer staples shares dipped by around 1.5%. Top Headline Constellation Brands Inc (NYSE:STZ) reported better-than-expected earnings for its second quarter. The company reported second-quarter FY24 net sales growth of 7% year-on-year to $2.84 billion, beating